Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pol θ-Helicase inhibitor
- Development stage
- Preclinical
- Lead developer
- QuantX Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pol θ-Helicase inhibitor is a preclinical-stage small molecule developed by QuantX Biosciences for the treatment of solid tumors. It specifically targets the helicase activity of DNA polymerase theta (Pol θ), a key component of the microhomology-mediated end joining (MMEJ) DNA repair pathway. This pathway serves as an alternative repair mechanism in cancer cells that are deficient in homologous recombination (HR), such as those with BRCA1 or BRCA2 mutations. By blocking Pol θ, the inhibitor aims to exploit synthetic lethality, leading to the accumulation of DNA damage and subsequent cell death in HR-deficient tumor cells while minimizing impact on normal cells.
- Other names
- Pol θ-Helicase inhibitor (unnamed)
02
Targets
Polθ HLD (Helicase domain of DNA polymerase theta)
Beyond the preview
Go deeper on Pol θ-Helicase inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pol θ-Helicase inhibitor.